Synergistic Brain Energy Support Systems

Publication ID: 24-11857527_0008_PTD
Published: October 28, 2025
Category:Synergistic Combinations

Legal Citation

pr1or.art Inc., “Synergistic Brain Energy Support Systems,” Published Technical Disclosure No. 24-11857527_0008_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857527_0008_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,527.

Summary of the Inventive Concept

The present invention relates to novel systems and methods that combine medium chain triglyceride compositions with advanced technologies such as AI, IoT, blockchain, and new materials to create more effective and personalized treatments for brain energy deficiency conditions and neurological disorders.

Background and Problem Solved

The original patent disclosed the use of medium chain triglyceride compositions for treating brain energy deficiency conditions and neurological disorders. However, these compositions have limitations in terms of personalized dosage, real-time monitoring, and secure supply chain management. The present invention addresses these limitations by integrating the original composition with advanced technologies to create a more powerful and efficient system.

Detailed Description of the Inventive Concept

The inventive concept comprises a medium chain triglyceride composition, which is administered to a subject in need of brain energy support. The composition is combined with one or more advanced technologies, such as AI-powered algorithms for personalized dosage recommendations, wearable devices for real-time monitoring of brain activity, blockchain-secured supply chain management, IoT-enabled data transmission modules, and novel delivery systems using graphene-based materials. The system provides a synergistic effect, enhancing the efficacy and safety of the treatment. For example, the AI-powered algorithm can analyze the subject's genomic data and brain activity to provide personalized dosage recommendations, while the blockchain-secured supply chain ensures the authenticity and quality of the composition.

Novelty and Inventive Step

The inventive concept is novel and non-obvious in that it combines the original medium chain triglyceride composition with advanced technologies to create a more powerful and efficient system for brain energy support. The integration of these technologies provides a synergistic effect, enhancing the efficacy and safety of the treatment. The inventive concept is not obvious from the original patent, as it requires a deep understanding of the interplay between the composition and the advanced technologies.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept include the use of different AI algorithms, wearable devices, or blockchain platforms. Variations of the inventive concept include the use of different medium chain triglyceride compositions, novel delivery systems, or additional advanced technologies such as transcranial magnetic stimulation or neural interfaces.

Potential Commercial Applications and Market

The inventive concept has significant commercial potential in the healthcare and nutrition industries, particularly in the areas of brain health and cognitive function. The market for brain health supplements is growing rapidly, and the inventive concept is well-positioned to capture a significant share of this market. Additionally, the inventive concept has potential applications in the pharmaceutical industry, particularly in the development of new treatments for neurological disorders.

Field of Art

Neurological treatment technologies, specifically medical compositions for brain energy support and metabolic interventions, requiring advanced knowledge in biochemistry, neuroscience, and medical device technologies

Person of Ordinary Skill (PHOSITA) Profile

A professional with advanced degrees in biochemistry or neuroscience, familiar with medical device integration, pharmaceutical formulation, and emerging technologies for neurological interventions

Obviousness Rationale

A PHOSITA would recognize that integrating digital technologies with established medical compositions represents a natural progression in personalized medical treatment. The source patent's MCT composition provides a foundational treatment method that can be readily enhanced through technological augmentation. The proposed variations represent predictable combinations of known technologies to improve diagnostic and treatment capabilities.

Obvious Combinations & Variations

Source Patent Element
MCT composition for treating brain energy deficiency conditions
PTD Variation
AI-powered personalized dosage recommendation algorithms
Obviousness Reasoning
Applying machine learning to medical dosing is a known technique, and personalizing treatment based on individual metabolic profiles represents a predictable extension of precision medicine approaches
Source Patent Element
Medium chain triglyceride treatment method
PTD Variation
Blockchain-secured supply chain management for composition delivery
Obviousness Reasoning
Implementing blockchain for pharmaceutical tracking is a standard industry approach to ensuring product authenticity and traceability, representing an obvious technological enhancement
Source Patent Element
Neurological condition treatment using MCT compositions
PTD Variation
IoT-enabled real-time brain activity monitoring devices
Obviousness Reasoning
Integrating sensor technologies for continuous medical monitoring is a well-established trend in digital health, providing predictable improvements in treatment tracking and patient management
Source Patent Element
MCT composition with specific fatty acid ratios
PTD Variation
Graphene-based novel delivery systems
Obviousness Reasoning
Exploring advanced material science for drug delivery represents a standard approach in pharmaceutical development, with graphene materials being a known emerging technology for enhanced molecular transport
35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857527 and the published technical disclosure, a person of ordinary skill in the art would find the proposed technological integrations with medium chain triglyceride compositions to be obvious variations. The combination of known medical compositions with emerging digital technologies represents a predictable and logical extension of existing neurological treatment methodologies, thereby rendering potential derivative claims non-patentable under standard obviousness criteria.

Original Patent Information

Patent NumberUS 11,857,527
TitleMedium chain triglyceride compositions
Assignee(s)SOCIÉTÉ DES PRODUITS NESTLÉ S.A.